ROCKVILLE, Md., Feb. 22 -- The FDA has ordered all drugs approved for attention deficit hyperactivity disorder to carry guides to inform patients about the potential for cardiovascular risks and adverse psychiatric symptoms.
"Medicines approved for the treatment of ADHD have real benefits for many patients but they may have serious risks as well," said Steven Galson, M.D., director of the FDA's Center for Drug Evaluation and Research.
<snip>
Fifteen products carry the revised labeling and will be accompanied in future by patient handouts. The products are:
* Adderall (mixed salts of a single entity amphetamine product) Tablets
* Adderall XR (mixed salts of a single entity amphetamine product) Extended-Release Capsules
* Concerta (methylphenidate hydrochloride) Extended-Release Tablets
* Daytrana (methylphenidate) Transdermal System
* Desoxyn (methamphetamine HCl) Tablets
* Dexedrine (dextroamphetamine sulfate) Spansule Capsules and Tablets
* Focalin (dexmethylphenidate hydrochloride) Tablets
* Focalin XR (dexmethylphenidate hydrochloride) Extended-Release Capsules
* Metadate CD (methylphenidate hydrochloride) Extended-Release Capsules
* Methylin (methylphenidate hydrochloride) Oral Solution
* Methylin (methylphenidate hydrochloride) Chewable Tablets
* Ritalin (methylphenidate hydrochloride) Tablets
* Ritalin SR (methylphenidate hydrochloride) Sustained-Release Tablets
* Ritalin LA (methylphenidate hydrochloride) Extended-Release Capsules
* Strattera (atomoxetine HCl) Capsules
link for full story includes links to draft Patient Medication Guides.